Pluri 授予 ZEO 再生医学产品组合的美国独家许可

Pluri 签订了一项合作协议，授予 ZEO 在美国制造和商业化其再生医学产品的独家许可（美容/护肤/化妆品/兽医用途的有限权利）。作为交换，Pluri 获得 ZEO 50% 的股权以及额外股权的认股权证、董事会提名权和特许权使用费。

关键事实

申报时间: 2026年10月30日 12:30
事件: 合作 / 授权交易
方向: 中性
公司: PLURPluri Inc.
资产: regenerative medicine product portfolio
来源: SEC 8-K
可信度: 有来源
股权份额: 50%
额外认股权证: 7.5%

来源摘录

false 0001158780 0001158780 2026-10-21 2026-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2026 ( October 21, 2026 ) PLURI INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-31392 98-0351734 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) MATAM Advanced Technology Park Building No. 5 Haifa , Israel 3508409 (Address of Principal Executive Offices) (Zip Code) 011 972 74 710 7171 (Registrant’s telephone number, including area code) (Former name or form

SEC 8-K